| Altered p53 functionality in cancer-associated fibroblasts contributes to their cancer-supporting features S Arandkar, N Furth, Y Elisha, NB Nataraj, H van der Kuip, Y Yarden, ... Proceedings of the National Academy of Sciences 115 (25), 6410-6415, 2018 | 95 | 2018 |
| TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment M Maddalena, G Mallel, NB Nataraj, M Shreberk-Shaked, O Hassin, ... Proceedings of the National Academy of Sciences 118 (23), e2025631118, 2021 | 80 | 2021 |
| AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer A Noronha, N Belugali Nataraj, JS Lee, B Zhitomirsky, Y Oren, S Oster, ... Cancer discovery 12 (11), 2666-2683, 2022 | 50 | 2022 |
| Proteomic patterns associated with response to breast cancer neoadjuvant treatment A Shenoy, N Belugali Nataraj, G Perry, F Loayza Puch, R Nagel, I Marin, ... Molecular systems biology 16 (9), e9443, 2020 | 44 | 2020 |
| Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients O Hassin, NB Nataraj, M Shreberk-Shaked, Y Aylon, R Yaeger, ... Nature communications 13 (1), 2800, 2022 | 40 | 2022 |
| Navigator‐3, a modulator of cell migration, may act as a suppressor of breast cancer progression H Cohen‐Dvashi, N Ben‐Chetrit, R Russell, S Carvalho, M Lauriola, ... EMBO molecular medicine 7 (3), 299-314, 2015 | 39 | 2015 |
| Targeting HER3, a catalytically defective receptor tyrosine kinase, prevents resistance of lung cancer to a third-generation EGFR kinase inhibitor D Romaniello, I Marrocco, N Belugali Nataraj, I Ferrer, D Drago-Garcia, ... Cancers 12 (9), 2394, 2020 | 36 | 2020 |
| PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR S Ghosh, NB Nataraj, A Noronha, S Patkar, A Sekar, S Mukherjee, ... Cell reports 35 (8), 2021 | 31 | 2021 |
| Pancreatic cancer ascites xenograft–an expeditious model mirroring advanced therapeutic resistant disease T Golan, C Stossel, M Schvimer, D Atias, S Halperin, E Buzhor, ... Oncotarget 8 (25), 40778, 2017 | 28 | 2017 |
| Crosstalk between VEGF and novel angiogenic protein regulates tumor angiogenesis and contributes to aggressiveness of breast carcinoma NB Nataraj, BP Salimath Cellular signalling 25 (1), 277-294, 2013 | 21 | 2013 |
| ETS proteins bind with glucocorticoid receptors: relevance for treatment of Ewing sarcoma S Srivastava, NB Nataraj, A Sekar, S Ghosh, C Bornstein, D Drago-Garcia, ... Cell Reports 29 (1), 104-117. e4, 2019 | 20 | 2019 |
| Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors NB Nataraj, A Noronha, JS Lee, S Ghosh, HRM Raju, A Sekar, ... Cell reports 38 (8), 2022 | 17 | 2022 |
| Cross-talk between mutant p53 and p62/SQSTM1 augments cancer cell migration by promoting the degradation of cell adhesion proteins S Mukherjee, M Maddalena, YQ Lü, S Martinez, NB Nataraj, A Noronha, ... Proceedings of the National Academy of Sciences 119 (17), e2119644119, 2022 | 15 | 2022 |
| Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models I Marrocco, D Romaniello, I Vaknin, D Drago‐Garcia, R Oren, ML Uribe, ... EMBO Molecular Medicine 13 (4), e13144, 2021 | 14 | 2021 |
| TSHZ2 is an EGF-regulated tumor suppressor that binds to the cytokinesis regulator PRC1 and inhibits metastasis ML Uribe, M Dahlhoff, RN Batra, NB Nataraj, Y Haga, D Drago-Garcia, ... Science signaling 14 (688), eabe6156, 2021 | 12 | 2021 |
| Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53 M Lindzen, S Ghosh, A Noronha, D Drago, NB Nataraj, O Leitner, ... Oncogene 40 (21), 3665-3679, 2021 | 10 | 2021 |
| Treatment with anti-NAP monoclonal antibody reduces disease severity in murine model of novel angiogenic protein-induced or ovalbumin-induced arthritis NB Nataraj, J Krishnamurthy, BP Salimath Clinical & Experimental Immunology 171 (2), 155-163, 2013 | 10 | 2013 |
| Roles for growth factors and mutations in metastatic dissemination YY Nishanth Belugali Nataraj , Ilaria Marrocco Biochem Soc Trans, 2021 | 9 | 2021 |
| Inhibition of a pancreatic cancer model by cooperative pairs of clinically approved and experimental antibodies R Maron, B Schechter, NB Nataraj, S Ghosh, D Romaniello, I Marrocco, ... Biochemical and biophysical research communications 513 (1), 219-225, 2019 | 9 | 2019 |
| Regulation of nucleo-cytosolic 26S proteasome translocation by aromatic amino acids via mTOR is essential for cell survival under stress I Livneh, V Cohen-Kaplan, B Fabre, I Abramovitch, C Lulu, NB Nataraj, ... Molecular cell 83 (18), 3333-3346. e5, 2023 | 7 | 2023 |
Moshe OrenWeizmann Institute of Science, Israel在 weizmann.ac.il 的电子邮件经过验证
